CYNTHIA M BUTITTA
CIK 1222082 · Chief Operating Officer · last filed 2026-07-01
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$1.06M
Companies
6
Total Filings
64
Lifetime Open-Market Net
-$25.78M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| AUTL | Director | — | $1.45 | — | $0 | 1 | 2026-07-01 |
| URGN | Director | 2,000 | $40.88 | $81.8K | $0 | 9 | 2026-06-24 |
| OLMA | Director | 83,876 | $11.62 | $974.6K | $0 | 8 | 2026-06-23 |
| IPSC | Director | — | $2.05 | — | $0 | 5 | 2025-06-16 |
| Kite Pharma, Inc. (KITE) Delisted | Chief Operating Officer | 121,567 | — | — | -$25.78M | 38 | 2017-09-27 |
| MABVAX THERAPEUTICS HOLDINGS, INC. (TELK) Delisted | COO and CFO | — | — | — | $0 | 2 | 2009-11-18 |
Recent Filings · Page 3 of 7
64 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2020-11-19 | OLMA | Mixed | +83,876 | $369.6K | EDGAR |
| 2020-06-10 | URGN | Grant (A) | — | $0 | EDGAR |
| 2019-06-05 | URGN | Grant (A) | — | $0 | EDGAR |
| 2017-10-05 | — | Mixed | −121,567 | $0 | |
| 2017-09-27 | Kite Pharma, Inc. (KITE) Delisted | Mixed | +3,772 | -$759.6K | EDGAR |
| 2017-08-14 | Kite Pharma, Inc. (KITE) Delisted | Mixed | — | -$1.79M | EDGAR |
| 2017-07-11 | Kite Pharma, Inc. (KITE) Delisted | Mixed | — | -$1.53M | EDGAR |
| 2017-06-27 | Kite Pharma, Inc. (KITE) Delisted | Mixed | — | -$497.3K | EDGAR |
| 2017-06-27 | Kite Pharma, Inc. (KITE) Delisted | Sell (S) | −5,000 | -$504.0K | EDGAR |
| 2017-06-12 | Kite Pharma, Inc. (KITE) Delisted | Mixed | — | -$872.0K | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.